Key result
Current evidence does not support the discontinuation of ACE inhibitors or angiotensin receptor blockers in patients with COVID-19 and underlying kidney or cardiovascular diseases.
Why the study?
The functions of the ACE2-Ang-(1-7)-MasR axis and ACEi/ARBs are being re-evaluated due to hypotheses that ACEi/ARBs may increase SARS-CoV-2 infection risk by upregulating human ACE2 receptor expression.
Should ACEi/ARB therapies be stopped in COVID-19-infected patients with kidney or cardiovascular diseases?
Should ACEi/ARB therapies be stopped in COVID-19-infected patients with kidney or cardiovascular diseases?
This review highlights the need to re-evaluate the use of ACEi/ARBs in the COVID-19 era, balancing their established cardiovascular and renal benefits against theoretical risks of enhanced viral entry via ACE2.
Answers are grounded in this paper and cite their sources.
Continue ACEi/ARBs in COVID-19 patients with kidney or CV disease; leaves open need for RCTs.
In the decades since the discovery of angiotensin-converting enzyme 2 (ACE2), its protective role in terms of antagonizing activation of the classical renin-angiotensin system (RAS) axis has been recognized in clinical and experimental studies on kidney and cardiovascular diseases. The effects of ACE inhibitor/angiotensin type 1 receptor blockers (ACEi/ARBs) on ACE2-angiotensin-(1-7) (Ang- (1-7))-Mas receptor (MasR) axis activation has encouraged the use of such blockers in patients with kidney and cardiovascular diseases, until the emergence of coronavirus disease 2019 (COVID-19). The previously unchallenged functions of the ACE2-Ang-(1-7)-MasR axis and ACEi/ARBs are being re-evaluated in the era of COVID-19; the hypothesis is that ACEi/ARBs may increase the risk of severe acute respiratory syndrome coronavirus 2 infection by upregulating the human ACE2 receptor expression level. In this review, we examine ACE2 molecular structure, function (as an enzyme of the RAS), and distribution. We explore the roles played by ACE2 in kidney, cardiovascular, and pulmonary diseases, highlighting studies that defined the benefits imparted when ACEi/ARBs activated the local ACE2- Ang-(1-7)-MasR axis. Finally, the question of whether ACEi/ARBs therapies should be stopped in COVID-19-infected patients will be reviewed by reference to the available evidence.
No takes yet. Share an insight, caveat, or question.
Suh et al. (2020) conducted a review in COVID-19, Kidney Diseases, Cardiovascular Diseases. ACE inhibitors and Angiotensin II receptor blockers (ACEi/ARBs) vs. Discontinuation or non-use of ACEi/ARBs was evaluated. Current evidence does not support the discontinuation of ACE inhibitors or angiotensin receptor blockers in patients with COVID-19 and underlying kidney or cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: